|
Interagency Committee on Human Growth Hormone
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD, NIDDK, NINDS
|
The Committee was instituted to survey recipients of human growth hormone derived from pituitary glands that was distributed by NIH under an IND.
|
|
Interagency Committee on Smoking and Health
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA
|
NICHD, NCI, NHLBI, NIDA
|
The Interagency Committee on Smoking and Health (ICSH) coordinates Department of Health and Human Services research, educational programs, and other smoking and health effects with similar activities of other federal, state, local, and private agencies.
|
|
Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD)
|
Other
|
ACF, AHRQ, CDC, HRSA, IHS, SAMHSA
|
NIAAA, NIA, NICHD, NIDA
|
The Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences; the most recent was Oct. 31-Nov. 2, 2011 on Recognizing Alcohol-related neurodevelopmental disorder (ARND) in Primary Health Care of Children.
|
|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
Coordinates federal efforts to understand how pituitary human growth hormone may have led to the development of Creutzfeldt-Jakob Disease in participants of the National Hormone and Pituitary Program.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
|
Research Initiative
|
ATSDR, CDC, FDA
|
NIEHS, NCI, NEI, NIAID, NLM
|
The Interagency Coordinating Committee on the Validation of Alternative Methods is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientific valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting it. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints.
|
|
Interagency Dual Use Outreach Working Group (IDOWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Developiong strategies to educate the research community about DURC and the DURC-related USG policies
|
|
Interagency Federal Workgroup Meeting on the HIV Care Continuum
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA, OS, SAMHSA
|
OD/DPCPSI/OAR
|
Advisory Group of HIV experts assembled to develop a strategic plan on how to improve the retention of individuals within the HIV care continuum.
|
|
Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by HHS in response to the Congressional directive to address Alzheimer''''s disease. Under the National Alzheimer''s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran''s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency MERS-CoV Working Group on Medical Countermeasures
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
The Working Group focuses on potential MERS-CoV countermeasures, to include therapeutics (antivirals, monoclonals and others) and vaccines. The working group has been asked to assess the following:
a) inventory of what potential therapeutics (and vaccines) are under development/investigation by what groups
b) how far along are they in pre-clinical development (in-vitro, animal studies/mice/non- human primates) and what data are available
c) timelines for animal studies, scale-up, when could human trials be started – phase 1, phase 2, open-label studies
d) regulatory issues for IND, EUA, and clinical studies, safety issues
e) prioritization for clinical trials based upon pre-clinical data and scientific assessment of available data
|